LAURUSLABS

Laurus Labs Share Price

 

 

Invest in Laurus Labs with 3.32X leverage

Invest with MTF

Performance

  • Low
  • ₹1,103
  • High
  • ₹1,116
  • 52 Week Low
  • ₹501
  • 52 Week High
  • ₹1,119
  • Open Price₹1,110
  • Previous Close₹1,110
  • Volume806,060

Investment Returns

  • Over 1 Month + 7.64%
  • Over 3 Month + 27.06%
  • Over 6 Month + 48.52%
  • Over 1 Year + 79.97%

Smart Investing Starts Here Start SIP with Laurus Labs for Steady Growth!

Invest Now

Laurus Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 87.3
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 59,735
  • P/B Ratio
  • 12.4
  • Average True Range
  • 22.01
  • EPS
  • 12.67
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 22.94
  • RSI
  • 77.67
  • MFI
  • 77.76

Laurus Labs Financials

Laurus Labs Technicals

EMA & SMA

Current Price
₹1,106.50
-3.9 (-0.35%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,054.08
  • 50 Day
  • ₹1,007.22
  • 100 Day
  • ₹943.20
  • 200 Day
  • ₹840.65

Resistance and Support

1109.13 Pivot Speed
  • R3 1,131.97
  • R2 1,123.93
  • R1 1,117.17
  • S1 1,102.37
  • S2 1,094.33
  • S3 1,087.57

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Laurus Labs Ltd. is a leading pharmaceutical company specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs), focusing on anti-retrovirals, oncology, and cardiovascular treatments. It also provides contract development and manufacturing (CDMO) services globally.

Laurus Labs has an operating revenue of Rs. 6,358.39 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 9% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 14%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 37% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 77 which is a FAIR score but needs to improve its earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Laurus Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-23 Quarterly Results & Interim Dividend
2025-07-25 Quarterly Results
2025-04-24 Audited Results & Interim Dividend
2025-01-24 Quarterly Results
2024-10-24 Quarterly Results & Interim Dividend
Date Purpose Remarks
2025-10-31 INTERIM Rs.0.80 per share(40%)Interim Dividend
2025-05-09 INTERIM Rs.0.80 per share(40%)Second Interim Dividend
2024-11-06 INTERIM Rs.0.40 per share(20%)Interim Dividend
2024-05-08 INTERIM Rs.0.40 per share(20%)Interim Dividend
2023-11-02 INTERIM Rs.0.40 per share(20%)Interim Dividend
View Laurus Labs Dividend History Arrow

Laurus Labs F&O

Laurus Labs Shareholding Pattern

27.59%
8.53%
1.76%
26.17%
0%
23.34%
12.61%

Laurus Labs FAQs

Laurus Labs share price is ₹1,106 As on 02 January, 2026 | 14:44

The Market Cap of Laurus Labs is ₹59735.1 Cr As on 02 January, 2026 | 14:44

The P/E ratio of Laurus Labs is 87.3 As on 02 January, 2026 | 14:44

The PB ratio of Laurus Labs is 12.4 As on 02 January, 2026 | 14:44

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23